TOP TEN perturbations for 40047_at (Homo sapiens)

Organism: Homo sapiens
Gene: 40047_at
Selected probe(set): 201962_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 40047_at (201962_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):-2.499961
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):2.4692793
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):2.328682
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):2.317194
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

HIV-associated neurocognitive disorder study 7 (normal) / HIV-associated neurocognitive disorder study 6 (normal)

Relative Expression (log2-ratio):2.2459402
Number of Samples:2 / 2
Experimental HIV-associated neurocognitive disorder study 7 (normal)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with normal brain pathology. The patients received antiretroviral therapy (ART).
Control HIV-associated neurocognitive disorder study 6 (normal)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with normal brain pathology. The patients did not receive any antiretroviral therapy (ART).

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):2.2032862
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

HIV-associated neurocognitive disorder study 7 (normal) / normal genu sample

Relative Expression (log2-ratio):2.1246214
Number of Samples:2 / 8
Experimental HIV-associated neurocognitive disorder study 7 (normal)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with normal brain pathology. The patients received antiretroviral therapy (ART).
Control normal genu sample
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from healthy subjects.

atypical teratoid/rhabdoid tumor study 1 / non-tumor brain tissue

Relative Expression (log2-ratio):-2.0143938
Number of Samples:20 / 9
Experimental atypical teratoid/rhabdoid tumor study 1
Primary tumor tissue sample from the brain of pediatric patients with atypical teratoid/rhabdoid tumor (AT/RT).
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

brain tumor study 1 (ependymoma) / normal brain tissue

Relative Expression (log2-ratio):-1.9155293
Number of Samples:46 / 12
Experimental brain tumor study 1 (ependymoma)
Primary tumor tissue sample from the brain of patients with ependymoma.
Control normal brain tissue
Histologically normal and non-neoplastic tissue sample from different brain anatomical sites of patients with primary brain tumors.

glioma study 5 / non-tumor brain tissue

Relative Expression (log2-ratio):-1.7515688
Number of Samples:12 / 9
Experimental glioma study 5
Primary tumor tissue sample from the supratentorial brain of pediatric patients with glioblastoma multiformae.
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.